E137: Obexelimab in IgG4-RD (INDIGO)
About this episode
The episode discusses the new B cell drug Obexelimab as a treatment option for IgG4-RD, highlighting its potential efficacy and toxicity compared to existing treatments.
Another day, another B cell drug. This one adds an interesting option for IgG4-RD, offering a "maybe less efficacious maybe less toxic" pathway. I could see folks being excited for this, especially in a disease where non-scary-manifestations are relatively common. Also, check out boardsbank.com! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2601337
Sponsors
boardsbank.com
More episodes of The Evidence Based Rheumatology Podcast
Explore listener stats, chart rankings, contacts and more on the The Evidence Based Rheumatology Podcast podcast page.